

based on this information and each application is scored and ranked.

In addition, the following factors may affect the funding decision:

- Availability of funds
- Relevance to program priorities.

Applications will be funded in order by score and rank determined by the review panel. CDC/ATSDR will provide justification for any decision to fund out of rank order.

V.3. Anticipated Announcement and Award Dates

The anticipated announcement date is November 1, 2004 and the award dates will be 30–60 days before the conferences begin.

VI. Award Administration Information

VI.1. Award Notices

Successful applicants will receive a Notice of Grant Award (NGA) from the CDC Procurement and Grants Office. The NGA shall be the only binding, authorizing document between the recipient and CDC. The NGA will be signed by an authorized Grants Management Officer, and mailed to the recipient fiscal officer identified in the application.

Unsuccessful applicants will receive notification of the results of the application review by mail.

VI.2. Administrative and National Policy Requirements

45 CFR part 74 and part 92.

For more information on the Code of Federal Regulations, see the National Archives and Records Administration at the following Internet address: <http://www.access.gpo.gov/nara/cfr/cfr-table-search.html>.

The following additional requirements apply to this project:

- AR–7 Executive Order 12372.
- AR–9 Paperwork Reduction Act Requirements.
- AR–10 Smoke-Free Workplace Requirements.
- AR–11 Healthy People 2010.
- AR–12 Lobbying Restrictions.
- AR–13 Prohibition on Use of CDC Funds for Certain Gun Control Activities.
- AR–15 Proof of Non-Profit Status.
- AR–20 Conference Support.

Additional information on these requirements can be found on the CDC Web site at the following Internet address: <http://www.cdc.gov/od/pgo/funding/ARs.htm>.

VI.3. Reporting Requirements

You must provide CDC with an original, plus two hard copies of the following reports:

1. Interim progress report, due no less than 90 days before the end of the budget period.

2. Financial status report, due no later than 90 days after the end of the budget period/project.

These reports must be mailed to the Grants Management or Contract Specialist listed in the “Agency Contacts” section of this announcement.

VII. Agency Contacts

We encourage inquiries concerning this announcement.

For general questions, contact: Technical Information Management Section, CDC Procurement and Grants Office, 2920 Brandywine Road, Atlanta, GA 30341, telephone: 770–488–2700.

For program technical assistance, contact: Refer to the Attachment for contacts listed per each center.

For business management assistance, contact: Edna Green, Grants Management Specialist, CDC Procurement and Grants Office, 2920 Brandywine Road, Atlanta, GA 30341, telephone: 770–488–2743. e-mail: egreen@cdc.gov.

VIII. Other Information

This and other CDC funding opportunity announcements can be found on the CDC Web site, Internet address: <http://www.cdc.gov>. Click on “Funding” then “Grants and Cooperative Agreements.”

Dated: October 27, 2004.

William P. Nichols,

Acting Director, Procurement and Grants Office, Centers for Disease Control and Prevention.

Attachment

Topic Areas of Programmatic Interest and Contact Information

100. Agency for Toxic Substances and Disease Registry (ATSDR)—LaShonda Billingsley, (404) 498–0275, LBillingsley@cdc.gov.
- 100.1 Health effects of hazardous substances in the environment;
- 100.2 Disease and toxic substance exposure registries;
- 100.3 Hazardous substance removal and remediation;
- 100.4 Emergency Response to toxic and environmental disasters;
- 100.5 Risk communication;
- 100.6 Environmental Disease Surveillance;
- 100.7 Investigation and research on hazardous substances in the environment
300. National Center on Birth Defects and Developmental Disabilities (NCBDDD)—Sheryl Heard, (404) 498–3978, SHeard@cdc.gov.
- 300.1 Birth Defects
- 300.2 Fetal Alcohol Syndrome
- 300.3 Disabilities: Issues related to people with disabilities; health promotion and intervention for persons with disabilities;

secondary conditions; and aging and disability;

300.4 Newborn and Childhood screening: Hearing, metabolic, genetic, and developmental

300.5 Hearing Loss, early interventions, genetic causes

300.6 Mental Retardation

300.7 Child Development

300.8 Autism Spectrum Disorders and Other Developmental Disabilities

300.9 Hereditary Blood Disorders

500. National Center for Environmental Health (NCEH)—LaShona Billingsley, (404) 498–0275, LBillingsley@cdc.gov.

500.1 Genetics and Disease Prevention

500.2 Emergency and Environmental Health Services (lead poisoning, environmental health hazards)

500.3 Environmental Hazards and Health Effects (air pollution, asthma, health studies)

500.4 Division of Laboratory Sciences (air toxins, newborn screening)

600. National Center HIV, STD, and TB Prevention (NCHSTP)—Beth Wolfe, (404) 639–8531, BWolfe@cdc.gov.

600.1 Sexually Transmitted Diseases (not HIV)

600.2 Tuberculosis in Foreign Born Persons in the United States

600.3 Tuberculosis in African American Populations in the United States (especially in the Southeast)

600.4 Therapeutics and Diagnostics

800.0 National Center for Injury Prevention and Control (NCIPC)—Benjamin Moore, (770) 488–4710, Moore@cdc.gov.

800.1 Unintentional Injuries Prevention

800.2.1 National level conferences that focus on preventing child maltreatment before it occurs (primary prevention)

800.2.2 National level conferences that focus on preventing youth violence before it occurs (primary prevention)

800.3 Acute Injury Care

800.4 Traumatic Brain Injury (TBI)

800.5 Injury Related Disability

800.6 Preparedness and Response for Injuries Resulting from Mass Causality Events and/or Terrorist Attacks

800.7 Impact Biomechanics

1500. Public Health Practice Program Office (PHPPPO)—Janet Telman, (770) 488–2834, JTelman@cdc.gov.

1500.1 Laboratory Practice

1500.2 Training and Materials

[FR Doc. 04–24390 Filed 11–1–04; 8:45 am]

BILLING CODE 4163–18–P

DEPARTMENT OF HEALTH AND HUMAN SERVICES

Centers for Disease Control and Prevention

National Task Force on Fetal Alcohol Syndrome and Fetal Alcohol Effect

In accordance with section 10(a)(2) of the Federal Advisory Committee Act (Pub. L. 92–463), the Centers for Disease Control and Prevention (CDC)

announces the following Federal advisory committee meeting.

NAME: National Task Force on Fetal Alcohol Syndrome and Fetal Alcohol Effect (NTFFASFAE).

TIMES AND DATES: 9 a.m.–4:30 p.m., December 6, 2004; 9 a.m.–12 noon, December 7, 2004.

PLACE: Westin Buckhead Atlanta Hotel, 3391 Peachtree Road, NE., 30326, telephone (404) 365–0065, fax (404) 365–8787.

STATUS: Open to the public, limited only by the space available. The meeting room accommodates approximately 65 people.

PURPOSE: The Secretary is authorized by the Public Health Service Act, Section 399G, (42 U.S.C. S 280f, as added by Public Law 105–392) to establish a National Task Force on Fetal Alcohol Syndrome and Fetal Alcohol Effect to: (1) Foster coordination among all governmental agencies, academic bodies and community groups that conduct or support Fetal Alcohol Syndrome (FAS) and Fetal Alcohol Effect (FAE) research, programs and surveillance; and (2) to otherwise meet the general needs of populations actually or potentially impacted by FAS and FAE.

MATTERS TO BE DISCUSSED: Agenda items include: An overview of effective strategies to reduce the risk of problem drinking and alcohol-exposed pregnancies; what is needed to implement effective programs in the service delivery system; alcohol advertising and adolescent girls; and a discussion of issues presented. Additional agenda items include: Prevention and Post-Exposure working group sessions; updates from Task Force members on current initiatives; an update on activities from the Interagency Coordinating Committee on Fetal Alcohol Syndrome, the CDC and other Federal agencies; future topics, and scheduling the next meeting.

Agenda items are subject to change as priorities dictate.

FOR FURTHER INFORMATION CONTACT: R. Louise Floyd, DSN, RN, Designated Federal Official, National Center on Birth Defects and Developmental Disabilities, CDC, 1600 Clifton Road, NE., (E–86), Atlanta, Georgia 30333, telephone (404) 498–3923, fax (404) 498–3550.

The Director, Management Analysis and Services Office, has been delegated the authority to sign **Federal Register** notices pertaining to announcements of meetings and other committee management activities for both the CDC and ATSDR.

Dated: October 27, 2004.

B. Kathy Skipper,

Acting Director, Management Analysis and Services Office, Centers for Disease Control and Prevention.

[FR Doc. 04–24391 Filed 11–1–04; 8:45 am]

BILLING CODE 4163–18–P

DEPARTMENT OF HEALTH AND HUMAN SERVICES

Centers for Disease Control and Prevention

The Board of Scientific Counselors, National Center for Environmental Health/Agency for Toxic Substances and Disease Registry

In accordance with section 10(a)(2) of the Federal Advisory Committee Act (Pub. L. 92–463), the Centers for Disease Control and Prevention (CDC) and the National Center for Environmental Health/Agency for Toxic Substances and Disease Registry (ATSDR) announce the following committee meeting:

Name: Board of Scientific Counselors (BSC), National Center for Environmental Health/Agency for Toxic Substances and Disease Registry (NCEH/ATSDR).

Time and Dates: 8:30 a.m.–5 p.m., November 18, 2004, 8:30 a.m.–12:30 p.m., November 19, 2004.

Place: CDC Headquarters facility, 1600 Clifton Road, Atlanta, GA 30333.

Status: Open to the public for observation, limited only by the space available. The meeting room accommodates approximately 100 people.

Purpose: The Secretary, and by delegation, the Director of the Centers for Disease Control and Prevention and the Administrator of the National Center for Environmental Health/Agency for Toxic Substances and Disease Registry, are authorized under section 301 (42 U.S.C. 241) and section 311 (42 U.S.C. 243) of the Public Health Service Act, as amended, to (1) conduct, encourage, cooperate with, and assist other appropriate public authorities, scientific institutions, and scientists in the conduct of research, investigations, experiments, demonstrations, and studies relating to the causes, diagnosis, treatment, control, and prevention of physical and mental diseases and other impairments; (2) assist States and their political subdivisions in the prevention of infectious diseases and other preventable conditions and in the promotion of health and well-being; and (3) train State and local personnel in health work. The Board of Scientific Counselors, NCEH/ATSDR provides advice and guidance to the Secretary, HHS; the Director, CDC and Administrator, ATSDR; and the Director, NCEH/ATSDR, regarding program goals, objectives, strategies, and priorities in fulfillment of the agencies' mission to protect and promote people's health. The Board provides advice and guidance that will assist NCEH/ATSDR in ensuring scientific quality, timeliness, utility, and dissemination of

results. The Board also provides guidance to help NCEH/ATSDR work more efficiently and effectively with its various constituents and to fulfill its mission in protecting America's health.

Matters To Be Discussed: The agenda items for the meeting on November 18–19, 2004, will include but are not limited to an update on future initiatives; update on NCEH/ATSDR consolidation and accomplishments; reports on the Program Peer Review and the Community and Tribal subcommittees and the Health Department Workgroup; update on NCEH/ATSDR strategic priorities; report on social/behavioral sciences at NCEH/ATSDR; a review of the ATSDR Draft Dioxin Soil Policy Guidelines; and a presentation on the Emergency Preparedness and Response activities at NCEH/ATSDR.

Agenda items are tentative and subject to change.

For Further Information Contact:

Individuals interested in attending the meeting, please contact Sandra Malcom, Committee Management Specialist, NCEH/ATSDR, 1600 Clifton Road, Mail Stop E–28, Atlanta, GA 30303; telephone 404/498–0003, fax 404/498–0059; e-mail: smalcom@cdc.gov. The deadline for notification of attendance is November 12, 2004.

The Director, Management Analysis and Services Office, has been delegated the authority to sign **Federal Register** notices pertaining to announcements of meetings and other committee management activities for both CDC and the National Center for Environmental Health/Agency for Toxic Substances and Disease Registry.

Dated: October 27, 2004.

B. Kathy Skipper,

Acting Director, Management Analysis and Services Office, Centers for Disease Control and Prevention.

[FR Doc. 04–24389 Filed 11–1–04; 8:45 am]

BILLING CODE 4163–18–P

DEPARTMENT OF HEALTH AND HUMAN SERVICES

Food and Drug Administration

[Docket No. 2002E–0340]

Determination of Regulatory Review Period for Purposes of Patent Extension; GANIRELIX ACETATE INJECTION (Formerly ANTAGON)

AGENCY: Food and Drug Administration, HHS.

ACTION: Notice.

SUMMARY: The Food and Drug Administration (FDA) has determined the regulatory review period for GANIRELIX ACETATE INJECTION and is publishing this notice of that determination as required by law. FDA has made the determination because of the submission of an application to the Director of Patents and Trademarks, Department of Commerce, for the